Atlas Trials

PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer

Clinical trial NCT02331927 · UNKNOWN

Trial details

NCT number
NCT02331927
Sponsor
University of Ulm
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Colorectal Cancer
Start date
2015-03-01
Primary completion
2020-03-01
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.